Scene 1

Integrantes: Álvaro Beltrán Jeanissa Cárdenas Fernanda Raiman Carla Rivera Gabriela Rubilar Cristian Valdebenito

La Etiqueta De Titulo Cinta Cinta, Azul, Cinta, Veces PNG y Vector para  Descargar Gratis | Pngtree

Ayudante alumna: Alexandra Gotschlich Docente: Héctor Contreras Biología Celular y Molecular 2020, Medicina

Scene 2

Figura 1:  CEB. ¿SERAN LOS EXOSOMAS EL PROXIMO CABALLO GANADOR? [Internet]. Edu.es. [citado el 15 de marzo de 2021]. Disponible en: https://ceb.edu.es/seran-los-exosomas-el-proximo-caballo-ganador/

SERAN LOS EXOSOMAS EL PROXIMO CABALLO GANADOR?

Scene 3

Figura 2: Diagrama de elaboración propia. Fuente: Corcoran C, Rani S, O'Driscoll L. miR‐34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. The Prostate, 2014-09, Vol.74 (13), p.1320-1334.

mRNA de
BCL-2
t miRNA-34a
BCL-2
m iRNA-34a
miRNA-ua
BCL-2
Salida de
citocromo C
Activaciön de
caspasas
1
Activaci6n de
nucleasas
Fragmentaciön
del DNA

Exosomas  de líneas celulares resistentes a  docetaxel  presentan baja expresión de miRNA-34a

Scene 4

miR-375
Epithelial
differentiation
EMT
Tumor cell
Invasion

Figura 3: Diagrama extraído desde Selth L, Das R, Townley S, Coutinho I, Hanson A, Centenera M et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. 2016;36(1):24-34.

Mayor expresiön de
YAPI en lineas celulares
de
Disminuciön de
YAPI
Baja expresiön
de miRNA-375
miRNA-375
de
de
EMT
MET
Suprsiön
de tumor
Aumento
miRNA-375
ZEBI
Disminuciön
Vim y FN-1
Disminuci6n
invasiön, migraciön
y crecimiento

Figura 4: Diagrama de elaboración propia. Fuente: Selth L, Das R, Townley S, Coutinho I, Hanson A, Centenera M et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. 2016;36(1):24-34.

Scene 5

Sigue sin determinarse un papel directo de miR-1290 en el cáncer de próstata. Altos niveles de miR-1290 se relaciona con la peor sobrevida global de pacientes con CRPC.

Figura 5: Diagrama de elaboración propia. Fuente: Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T et al. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer. Endocrine-Related Cancer. 2012;20(1):91-102.

Scene 6

Figura 6: Diagrama de elaboración propia. Fuente: Guo T, Wang Y, Jim J, Mao X, Stankiewicz E, Scandura G te al. The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing. Front Cell Dev Biol. 2021. 7;8;602493.

CRPC -...............................................................................> miRNA-423-3P en exosomas
CP sin miRNA-423-3p en exosomas
CP sin tratamiento miRNA-423-3p en exosomas
cp con ADT miRNA-423-3P en exosomas

Scene 7

Chromosome
xR.FL Gene 5
t' anscript
.V7 Gene
ranscript
-R protein
AR.FL mRNA
exon 3
t 3 UTR
AR-VI mRNA
Hinge region
AR-VI -spec hc

Figura 7: Zhang T, Karsh L, Nissenblatt M, Canfield S. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. Clinical Genitourinary Cancer. 2019; 18 (1): 1-10

Scene 8

Figura 8: Diagrama de elaboración propia. Fuente: Lin C, Yun EJ, Lo UG, Tai Y, Deng S, Hernandez E, et al. The paracrine induction of prostate cancer progression by caveolin-1. Cell Death and Disease. 2019;10:834.

Proliferación Supervivencia Metástasis Resistencia

IkBa
NF-kB1
NF-kB1
IKKß
OCT 4 KLF4
SOX2 y C-MYC

Scene 9

Posible análisis junto a otros exámenes

Figura 9:  imagen de elaboración propia.

Scene 10

Figura 10:  imagen de elaboración propia.

Aislado Icono De La Casa Con La Señal Verde Fotos, Retratos, Imágenes Y  Fotografía De Archivo Libres De Derecho. Image 78862412.

Vector símbolo de la Cruz Roja no vale | Vectores de dominio público

Utilidad de  biomarcadores  en  exosomas  plasmáticos

Scene 11

(1) Corcoran C, Rani S, O'Driscoll L. miR‐34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. The Prostate, 2014-09, Vol.74 (13), p.1320-1334. (2) Sanaz N,  Ali M,  Pascal H, Behzad B,  Elham S,  William C, Behzad M. The role of miR‐34 in cancer drug resistance. Journal of cellular physiology, 2020-10, Vol.235 (10), p.6424-6440. Disponible en:  https://onlinelibrary-wiley-com.uchile.idm.oclc.org/doi/10.1002/jcp.29640 (3) Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R et al. Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer. European Urology. 2015;67(1):33-41. (4) Selth L, Das R, Townley S, Coutinho I, Hanson A, Centenera M et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. 2016;36(1):24-34. (5) Guo T, Wang Y, Jia J, Mao X, Stankiewicz E, Scandura G, et al. The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing. Front. Cell Dev. Biol. 2021; 8:602493.Guo T, Wang Y, Jia J, Mao X, Stankiewicz E, Scandura G, et al. The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing.  Front Cell Dev Biol. 2021. 7;8:602493. (6) Nimir M, Ma Y, Jeffreys S, Opperman T, Young F, Khan T, et al. Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes. Cells. 2019, 8, 688. (7) Lin C, Yun EJ, Lo UG, Tai Y, Deng S, Hernandez E, et al. The paracrine induction of prostate cancer progression by caveolin-1. Cell Death and Disease. 2019;10:834.  (8) Pereira V. Tapia G. Bologna R. CAVEOLINA-1 implicaciones fisiológicas y patológicas. Odontoestomatología. Montevideo, Uruguay. 2017; 19 (30): 92-98.

Marcadores

Scene 0

 (1) Corcoran C, Rani S, O'Driscoll L. miR‐34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. The Prostate, 2014-09, Vol.74 (13), p.1320-1334. (2) Sanaz N,  Ali M,  Pascal H, Behzad B,  Elham S,  William C, Behzad M. The role of miR‐34 in cancer drug resistance. Journal of cellular physiology, 2020-10, Vol.235 (10), p.6424-6440. Disponible en:  https://onlinelibrary-wiley-com.uchile.idm.oclc.org/doi/10.1002/jcp.29640 (3) Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R et al. Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer. European Urology. 2015;67(1):33-41. (4) Selth L, Das R, Townley S, Coutinho I, Hanson A, Centenera M et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. 2016;36(1):24-34. (5) Guo T, Wang Y, Jia J, Mao X, Stankiewicz E, Scandura G, et al. The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing. Front. Cell Dev. Biol. 2021; 8:602493.Guo T, Wang Y, Jia J, Mao X, Stankiewicz E, Scandura G, et al. The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing.  Front Cell Dev Biol. 2021. 7;8:602493. (6) Nimir M, Ma Y, Jeffreys S, Opperman T, Young F, Khan T, et al. Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes. Cells. 2019, 8, 688. (7) Lin C, Yun EJ, Lo UG, Tai Y, Deng S, Hernandez E, et al. The paracrine induction of prostate cancer progression by caveolin-1. Cell Death and Disease. 2019;10:834.  (8) Pereira V. Tapia G. Bologna R. CAVEOLINA-1 implicaciones fisiológicas y patológicas. Odontoestomatología. Montevideo, Uruguay. 2017; 19 (30): 92-98.

Marcadores

Page 1 (0s)

Page 2 (12s)

Page 3 (1m 38s)

Page 4 (2m 54s)

Page 5 (4m 40s)

Page 6 (5m 43s)

Page 7 (6m 59s)

Page 8 (8m 16s)

Page 9 (9m 37s)

Page 10 (10m 31s)

Page 11 (11m 2s)